BACKGROUND: Few randomized trials have been conducted in children with relapsed/refractory neuroblastoma and data about outcomes including progression-free survival (PFS) in these patients are scarce. PROCEDURE: A meta-analysis of three phase II studies of children with relapsed/refractory neuroblastoma conducted in Europe (temozolomide, topotecan-vincristine-doxorubicin and topotecan-temozolomide) was performed. Individual patient data with extended follow-up were collected from the trial databases after publication to describe trial outcomes (response rate, clinical benefit ratio, duration of treatment, PFS, and overall survival [OS]). Characteristics of subjects with relapsed/refractory neuroblastoma were compared. RESULTS: Data from 71 children and adolescents with relapsed/refractory neuroblastoma were collected. Response definitions were not homogeneous in the three trials. Patients were on study for a median of 3.5 months (interquartile range [IQR] 1.9-6.2). Of those, 35.2% achieved a complete or partial response, 26.3% experienced a response after more than two cycles, and 23.9% received more than six cycles. Median PFS from study entry for all, refractory, and relapsed patients was 6.4 ± 1.0, 12.5 ± 6.8, and 5.7 ± 1.0 months, respectively (P = 0.006). Median OS from study entry for all, refractory, and relapsed patients was 16.1 ± 4.3, 27.9 ± 20.2, and 11.0 ± 1.6 months, respectively (P = 0.03). CONCLUSIONS: Baseline data for response rate, clinical benefit ratio, duration of treatment, PFS, and OS were provided. Two subpopulations (relapsed/refractory) were clearly distinct and should be included in the interpretation of all trials. These results should help informing the design of forthcoming studies in relapsed/refractory neuroblastoma.
BACKGROUND: Few randomized trials have been conducted in children with relapsed/refractory neuroblastoma and data about outcomes including progression-free survival (PFS) in these patients are scarce. PROCEDURE: A meta-analysis of three phase II studies of children with relapsed/refractory neuroblastoma conducted in Europe (temozolomide, topotecan-vincristine-doxorubicin and topotecan-temozolomide) was performed. Individual patient data with extended follow-up were collected from the trial databases after publication to describe trial outcomes (response rate, clinical benefit ratio, duration of treatment, PFS, and overall survival [OS]). Characteristics of subjects with relapsed/refractory neuroblastoma were compared. RESULTS: Data from 71 children and adolescents with relapsed/refractory neuroblastoma were collected. Response definitions were not homogeneous in the three trials. Patients were on study for a median of 3.5 months (interquartile range [IQR] 1.9-6.2). Of those, 35.2% achieved a complete or partial response, 26.3% experienced a response after more than two cycles, and 23.9% received more than six cycles. Median PFS from study entry for all, refractory, and relapsed patients was 6.4 ± 1.0, 12.5 ± 6.8, and 5.7 ± 1.0 months, respectively (P = 0.006). Median OS from study entry for all, refractory, and relapsed patients was 16.1 ± 4.3, 27.9 ± 20.2, and 11.0 ± 1.6 months, respectively (P = 0.03). CONCLUSIONS: Baseline data for response rate, clinical benefit ratio, duration of treatment, PFS, and OS were provided. Two subpopulations (relapsed/refractory) were clearly distinct and should be included in the interpretation of all trials. These results should help informing the design of forthcoming studies in relapsed/refractory neuroblastoma.
Authors: Jennifer W Mack; Hajime Uno; Clare J Twist; Rochelle Bagatell; Abby R Rosenberg; Araz Marachelian; M Meaghan Granger; Julia Glade Bender; Justin N Baker; Julie R Park; Susan L Cohn; Jorge H Fernandez; Lisa R Diller; Suzanne Shusterman Journal: J Pain Symptom Manage Date: 2020-04-30 Impact factor: 3.612
Authors: Sarah B Whittle; Valeria Smith; Allison Silverstein; Margaret Parmeter; Charles G Minard; M Brooke Bernhardt; Peter E Zage; Rajkumar Venkatramani; Jed G Nuchtern; Andras Heczey; Heidi V Russell; Jason M Shohet; Jennifer H Foster Journal: Pediatr Blood Cancer Date: 2020-07-30 Impact factor: 3.167
Authors: Julie R Park; Susan G Kreissman; Wendy B London; Arlene Naranjo; Susan Lerner Cohn; Michael D Hogarty; Sheena C Tenney; Daphne Haas-Kogan; Peter John Shaw; Jacqueline M Kraveka; Stephen S Roberts; James Duncan Geiger; John J Doski; Stephan D Voss; John M Maris; Stephan A Grupp; Lisa Diller Journal: JAMA Date: 2019-08-27 Impact factor: 56.272
Authors: Marie Menard; Benjamin A H Smith; Miles H Linde; Johanna Theruvath; Garry L Coles; Guillermo Nicolas Dalton; Wei Wu; Louise Kiru; Alberto Delaidelli; Elena Sotillo; John L Silberstein; Anna C Geraghty; Allison Banuelos; Molly Thomas Radosevich; Shaurya Dhingra; Sabine Heitzeneder; Aidan Tousley; John Lattin; Peng Xu; Jing Huang; Nicole Nasholm; Andy He; Tracy C Kuo; Emma R B Sangalang; Jaume Pons; Amira Barkal; Rachel E Brewer; Kristopher D Marjon; Jose G Vilches-Moure; Payton L Marshall; Ricardo Fernandes; Michelle Monje; Jennifer R Cochran; Poul H Sorensen; Heike E Daldrup-Link; Irving L Weissman; Julien Sage; Ravindra Majeti; Carolyn R Bertozzi; William A Weiss; Crystal L Mackall; Robbie G Majzner Journal: Nat Med Date: 2022-01-13 Impact factor: 87.241
Authors: Shakeel Modak; Jean-Benoit Le Luduec; Irene Y Cheung; Debra A Goldman; Irina Ostrovnaya; Ekaterina Doubrovina; Ellen Basu; Brian H Kushner; Kim Kramer; Stephen S Roberts; Richard J O'Reilly; Nai-Kong V Cheung; Katharine C Hsu Journal: Oncoimmunology Date: 2018-05-10 Impact factor: 8.110
Authors: Karolina Łuczkowska; Katarzyna Ewa Sokolowska; Tomasz K Wojdacz; Bogusław Machaliński; Olga Taryma-Lesniak; Krzysztof Pastuszak; Anna Supernat; Jonas Bybjerg-Grauholm; Lise Lotte Hansen; Edyta Paczkowska Journal: Sci Rep Date: 2021-05-10 Impact factor: 4.379